Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest

Celularity Inc. (NASDAQ:CELU) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 743,700 shares, a growth of 9.3% from the October 15th total of 680,500 shares. Based on an average daily volume of 876,800 shares, the short-interest ratio is currently 0.8 days. Approximately 6.9% of the company’s stock are short sold.

Celularity Stock Performance

Shares of NASDAQ CELU opened at $2.77 on Tuesday. Celularity has a twelve month low of $1.30 and a twelve month high of $7.97. The stock’s 50 day moving average price is $2.55 and its 200-day moving average price is $2.88.

Celularity (NASDAQ:CELU) last announced its earnings results on Wednesday, October 16th. The company reported ($1.03) earnings per share for the quarter. Celularity had a negative return on equity of 92.48% and a negative net margin of 264.30%. The business had revenue of $14.68 million during the quarter.

Hedge Funds Weigh In On Celularity

An institutional investor recently bought a new position in Celularity stock. Keynote Financial Services LLC purchased a new position in Celularity Inc. (NASDAQ:CELU) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned 0.08% of Celularity at the end of the most recent quarter. 19.02% of the stock is currently owned by institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.